Skip to main content
IncyteEarnings

A Noteworthy Decision By Lee Heeson As Acquires $130K In Incyte Stock Options

What happened

Incyte reported a gross margin of 91.79% and an EPS of 1.52.

Source

Article excerpt

Highlighted: the sentence this signal was extracted from

In a new SEC filing on July 27, it was unveiled that Heeson, EVP at Incyte (NASDAQ: INCY ), acquired stock options for 15,423 shares. As of Tuesday morning, Incyte shares are up by 5.3%, with a current price of $125.17. This implies that Heeson's 15,423 shares have a value of $130,864. Revenue Growth: Incyte's remarkable performance in 3 months is evident. As of 31 March, 2026, the company achieved an impressive revenue growth rate of 20.87%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector. Evaluating Earnings Performance: Gross Margin: The company sets a benchmark with a high gross margin of 91.79% , reflecting superior cost management and profitability compared to its peers. Earnings per Share (EPS): Incyte's EPS is below the industry average, signaling challenges in bottom-line performance with a current EPS of 1.52. Debt Management: Incyte's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.01. Valuation Metrics: Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential...

Keep reading with a free account

The rest of this article, and every signal for Incyte, is in your free account.

Extracted by Autobound

From the Signal API record
Event
Earnings

What this signalsEarnings results often set the next budget cycle.

The full record

From the Signal API record

Extraction

Confidence
90%
Detected
Jul 28, 2026
signal_type
news
signal_subtype
has_earnings

Use this data

Get every earnings signal for Incyte and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Incyte this week?”

  2. Send it to your own tools

    The Signal API returns earnings signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/07a2e7f0-79c2-c5c4-098c-86b1ae32c977 returns this record as JSON. POST /v1/companies/enrich returns every signal for incyte.com.

{
  "signal_id": "07a2e7f0-79c2-c5c4-098c-86b1ae32c977",
  "signal_type": "news",
  "signal_subtype": "has_earnings",
  "detected_at": "2026-07-28T15:00:45+00:00",
  "company": {
    "name": "Incyte",
    "domain": "incyte.com"
  },
  "data": {
    "url": "https://www.benzinga.com/news/26/07/60730466/noteworthy-decision-lee-heeson-acquires-130k-incyte-stock-options",
    "title": "A Noteworthy Decision By Lee Heeson As Acquires $130K In Incyte Stock Options - Benzinga",
    "excerpt": "In a new SEC filing on July 27, it was unveiled that Heeson, EVP at Incyte (NASDAQ: INCY ), acquired stock options for 15,423 shares. As of Tuesday morning, Incyte shares are up by 5.3%, with a current price of $125.17. This implies that Heeson's 15,423 shares have a value of $130,864. Revenue Growth: Incyte's remarkable performance in 3 months is evident. As of 31 March, 2026, the company achieved an impressive revenue growth rate of 20.87% . This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector. Evaluating Earnings Performance: Gross Margin: The company sets a benchmark with a high gross margin of 91.79% , reflecting superior cost management and profitability compared to its peers. Earnings per Share (EPS): Incyte's EPS is below the industry average, signaling challenges in bottom-line performance with a current EPS of 1.52 . Debt Management: Incyte's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.01 . Valuation Metrics: Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential...",
    "summary": "Incyte reported a gross margin of 91.79% and an EPS of 1.52.",
    "planning": false,
    "image_url": "https://cdn.benzinga.com/cdn-cgi/image/width=1200,height=800,fit=crop/files/images/story/2025/11/06/insider_trade_2.jpg",
    "confidence": 0.9,
    "published_at": "2026-07-28T15:00:45Z",
    "article_sentence": "Evaluating Earnings Performance: Gross Margin: The company sets a benchmark with a high gross margin of 91.79% , reflecting superior cost management and profitability compared to its peers."
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.